Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 146

1.

Pharmacokinetic and pharmacodynamic analysis of d-amphetamine in an attention task in rodents.

Slezak JM, Mueller M, Ricaurte GA, Katz JL.

Behav Pharmacol. 2018 Sep;29(6):551-556. doi: 10.1097/FBP.0000000000000409.

2.

Methylphenidate and impulsivity: a comparison of effects of methylphenidate enantiomers on delay discounting in rats.

Slezak JM, Ricaurte GA, Tallarida RJ, Katz JL.

Psychopharmacology (Berl). 2014 Jan;231(1):191-8. doi: 10.1007/s00213-013-3220-8. Epub 2013 Aug 24.

PMID:
23975034
3.

Behavioral effects and pharmacokinetics of (±)-3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) after intragastric administration to baboons.

Goodwin AK, Mueller M, Shell CD, Ricaurte GA, Ator NA.

J Pharmacol Exp Ther. 2013 Jun;345(3):342-53. doi: 10.1124/jpet.113.203729. Epub 2013 Mar 20.

4.

Studies of (±)-3,4-methylenedioxymethamphetamine (MDMA) metabolism and disposition in rats and mice: relationship to neuroprotection and neurotoxicity profile.

Mueller M, Maldonado-Adrian C, Yuan J, McCann UD, Ricaurte GA.

J Pharmacol Exp Ther. 2013 Feb;344(2):479-88. doi: 10.1124/jpet.112.201699. Epub 2012 Dec 3.

5.

Single oral doses of (±) 3,4-methylenedioxymethamphetamine ('Ecstasy') produce lasting serotonergic deficits in non-human primates: relationship to plasma drug and metabolite concentrations.

Mueller M, Yuan J, McCann UD, Hatzidimitriou G, Ricaurte GA.

Int J Neuropsychopharmacol. 2013 May;16(4):791-801. doi: 10.1017/S1461145712000582. Epub 2012 Jul 24.

PMID:
22824226
6.

Synthesis and neurotoxicity profile of 2,4,5-trihydroxymethamphetamine and its 6-(N-acetylcystein-S-yl) conjugate.

Neudörffer A, Mueller M, Martinez CM, Mechan A, McCann U, Ricaurte GA, Largeron M.

Chem Res Toxicol. 2011 Jun 20;24(6):968-78. doi: 10.1021/tx2001459. Epub 2011 May 18.

7.

Metabolism and disposition of 3,4-methylenedioxymethamphetamine ("ecstasy") in baboons after oral administration: comparison with humans reveals marked differences.

Mueller M, Goodwin AK, Ator NA, McCann UD, Ricaurte GA.

J Pharmacol Exp Ther. 2011 Jul;338(1):310-7. doi: 10.1124/jpet.111.180612. Epub 2011 Apr 14.

8.
9.

Dopamine is not essential for the development of methamphetamine-induced neurotoxicity.

Yuan J, Darvas M, Sotak B, Hatzidimitriou G, McCann UD, Palmiter RD, Ricaurte GA.

J Neurochem. 2010 Aug;114(4):1135-42. doi: 10.1111/j.1471-4159.2010.06839.x. Epub 2010 Jun 1.

10.

Sleep apnea in young abstinent recreational MDMA ("ecstasy") consumers.

McCann UD, Sgambati FP, Schwartz AR, Ricaurte GA.

Neurology. 2009 Dec 8;73(23):2011-7. doi: 10.1212/WNL.0b013e3181c51a62. Epub 2009 Dec 2.

11.

Sleep deprivation differentially impairs cognitive performance in abstinent methylenedioxymethamphetamine ("Ecstasy") users.

McCann UD, Wilson MJ, Sgambati FP, Ricaurte GA.

J Neurosci. 2009 Nov 4;29(44):14050-6. doi: 10.1523/JNEUROSCI.4654-09.2009.

12.

Further studies on the role of metabolites in (+/-)-3,4-methylenedioxymethamphetamine-induced serotonergic neurotoxicity.

Mueller M, Yuan J, Felim A, Neudörffer A, Peters FT, Maurer HH, McCann UD, Largeron M, Ricaurte GA.

Drug Metab Dispos. 2009 Oct;37(10):2079-86. doi: 10.1124/dmd.109.028340. Epub 2009 Jul 23.

13.

Direct comparison of (+/-) 3,4-methylenedioxymethamphetamine ("ecstasy") disposition and metabolism in squirrel monkeys and humans.

Mueller M, Kolbrich EA, Peters FT, Maurer HH, McCann UD, Huestis MA, Ricaurte GA.

Ther Drug Monit. 2009 Jun;31(3):367-73. doi: 10.1097/FTD.0b013e3181a4f6c2.

14.

Hydrolysis of 3,4-methylenedioxymethamphetamine (MDMA) metabolite conjugates in human, squirrel monkey, and rat plasma.

Mueller M, Kolbrich-Spargo EA, Peters FT, Huestis MA, Ricaurte GA, Maurer HH.

Anal Bioanal Chem. 2009 Mar;393(6-7):1607-17. doi: 10.1007/s00216-009-2607-1. Epub 2009 Jan 30.

16.
17.

Positron emission tomographic studies of brain dopamine and serotonin transporters in abstinent (+/-)3,4-methylenedioxymethamphetamine ("ecstasy") users: relationship to cognitive performance.

McCann UD, Szabo Z, Vranesic M, Palermo M, Mathews WB, Ravert HT, Dannals RF, Ricaurte GA.

Psychopharmacology (Berl). 2008 Oct;200(3):439-50. doi: 10.1007/s00213-008-1218-4. Epub 2008 Jul 27.

18.

Nonlinear pharmacokinetics of (+/-)3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") and its major metabolites in squirrel monkeys at plasma concentrations of MDMA that develop after typical psychoactive doses.

Mueller M, Peters FT, Maurer HH, McCann UD, Ricaurte GA.

J Pharmacol Exp Ther. 2008 Oct;327(1):38-44. doi: 10.1124/jpet.108.141366. Epub 2008 Jun 30.

PMID:
18591215
19.

Persistent cognitive and dopamine transporter deficits in abstinent methamphetamine users.

McCann UD, Kuwabara H, Kumar A, Palermo M, Abbey R, Brasic J, Ye W, Alexander M, Dannals RF, Wong DF, Ricaurte GA.

Synapse. 2008 Feb;62(2):91-100.

PMID:
17992686
20.

Effects of (+/-) 3,4-methylenedioxymethamphetamine (MDMA) on sleep and circadian rhythms.

McCann UD, Ricaurte GA.

ScientificWorldJournal. 2007 Nov 2;7:231-8. Review.

22.

Quantitative positron emission tomography studies of the serotonin transporter in humans previously treated with the appetite suppressants fenfluramine or dexfenfluramine.

McCann UD, Szabo Z, Vranesic M, Seckin E, Wand G, Duval A, Dannals RF, Ricaurte GA.

Mol Imaging Biol. 2007 May-Jun;9(3):151-7.

PMID:
17473958
23.

The effect of catecholamine depletion by alpha-methyl-para-tyrosine on measures of cognitive performance and sleep in abstinent MDMA users.

McCann UD, Peterson SC, Ricaurte GA.

Neuropsychopharmacology. 2007 Aug;32(8):1695-706. Epub 2007 Jan 3.

24.

Amphetamine treatment similar to that used in the treatment of adult attention-deficit/hyperactivity disorder damages dopaminergic nerve endings in the striatum of adult nonhuman primates.

Ricaurte GA, Mechan AO, Yuan J, Hatzidimitriou G, Xie T, Mayne AH, McCann UD.

J Pharmacol Exp Ther. 2005 Oct;315(1):91-8. Epub 2005 Jul 13.

PMID:
16014752
25.

Pharmacokinetic profile of single and repeated oral doses of MDMA in squirrel monkeys: relationship to lasting effects on brain serotonin neurons.

Mechan A, Yuan J, Hatzidimitriou G, Irvine RJ, McCann UD, Ricaurte GA.

Neuropsychopharmacology. 2006 Feb;31(2):339-50.

26.

Recognition and management of complications of new recreational drug use.

Ricaurte GA, McCann UD.

Lancet. 2005 Jun 18-24;365(9477):2137-45. Review.

PMID:
15964451
27.

Quantitative PET studies of the serotonin transporter in MDMA users and controls using [11C]McN5652 and [11C]DASB.

McCann UD, Szabo Z, Seckin E, Rosenblatt P, Mathews WB, Ravert HT, Dannals RF, Ricaurte GA.

Neuropsychopharmacology. 2005 Sep;30(9):1741-50.

28.

Identification and characterization of metallothionein-1 and -2 gene expression in the context of (+/-)3,4-methylenedioxymethamphetamine-induced toxicity to brain dopaminergic neurons.

Xie T, Tong L, McCann UD, Yuan J, Becker KG, Mechan AO, Cheadle C, Donovan DM, Ricaurte GA.

J Neurosci. 2004 Aug 11;24(32):7043-50.

29.
31.

Behavioral and neurochemical consequences of long-term intravenous self-administration of MDMA and its enantiomers by rhesus monkeys.

Fantegrossi WE, Woolverton WL, Kilbourn M, Sherman P, Yuan J, Hatzidimitriou G, Ricaurte GA, Woods JH, Winger G.

Neuropsychopharmacology. 2004 Jul;29(7):1270-81.

32.

Amphetamine neurotoxicity: accomplishments and remaining challenges.

McCann UD, Ricaurte GA.

Neurosci Biobehav Rev. 2004 Jan;27(8):821-6. Review.

PMID:
15019431
33.

Positron emission tomography of striatal serotonin transporters in Parkinson disease.

Kerenyi L, Ricaurte GA, Schretlen DJ, McCann U, Varga J, Mathews WB, Ravert HT, Dannals RF, Hilton J, Wong DF, Szabo Z.

Arch Neurol. 2003 Sep;60(9):1223-9.

PMID:
12975287
34.

Retraction.

Ricaurte GA, Yuan J, Hatzidimitriou G, Cord BJ, McCann UD.

Science. 2003 Sep 12;301(5639):1479. No abstract available.

PMID:
12970544
35.

Response to O'Shea and Colado: the MDMA neurotoxicity profile might provide clues to mechanisms.

Ricaurte GA, Yuan J, Hatzidimitriou G, Cord BJ, McCann UD.

Trends Pharmacol Sci. 2003 Jun;24(6):275. No abstract available.

PMID:
12823952
36.

Cognitive performance of MDMA-treated rhesus monkeys: sensitivity to serotonergic challenge.

Taffe MA, Davis SA, Yuan J, Schroeder R, Hatzidimitriou G, Parsons LH, Ricaurte GA, Gold LH.

Neuropsychopharmacology. 2002 Dec;27(6):993-1005.

38.

Effect of glucoprivation on serotonin neurotoxicity induced by substituted amphetamines.

Yuan J, Cord BJ, McCann UD, Callahan BT, Ricaurte GA.

J Pharmacol Exp Ther. 2002 Nov;303(2):831-9.

PMID:
12388670
39.
40.

Validity of [123I]beta-CIT SPECT in detecting MDMA-induced serotonergic neurotoxicity.

Reneman L, Booij J, Habraken JB, De Bruin K, Hatzidimitriou G, Den Heeten GJ, Ricaurte GA.

Synapse. 2002 Dec 1;46(3):199-205.

PMID:
12325046
41.

Use of MDMA and other illicit drugs by young adult males in northern Spain. A five-year study.

Bobes J, Sáiz PA, González MP, Bascarán MT, Bousoño M, Ricaurte GA, McCann UD.

Eur Addict Res. 2002 Jun;8(3):147-54.

PMID:
12065965
42.

Comparison of (+)-(11)C-McN5652 and (11)C-DASB as serotonin transporter radioligands under various experimental conditions.

Szabo Z, McCann UD, Wilson AA, Scheffel U, Owonikoko T, Mathews WB, Ravert HT, Hilton J, Dannals RF, Ricaurte GA.

J Nucl Med. 2002 May;43(5):678-92. Erratum in: J Nucl Med 2002 Jun;43(6):744.

43.

Effect of depleting vesicular and cytoplasmic dopamine on methylenedioxymethamphetamine neurotoxicity.

Yuan J, Cord BJ, McCann UD, Callahan BT, Ricaurte GA.

J Neurochem. 2002 Mar;80(6):960-9.

44.
45.

Effects of fenfluramine, m-CPP and triazolam on repeated-acquisition in squirrel monkeys before and after neurotoxic MDMA administration.

Winsauer PJ, McCann UD, Yuan J, Delatte MS, Stevenson MW, Ricaurte GA, Moerschbaecher JM.

Psychopharmacology (Berl). 2002 Feb;159(4):388-96. Epub 2001 Nov 23.

PMID:
11823891
46.

Changes in gene expression linked to methamphetamine-induced dopaminergic neurotoxicity.

Xie T, Tong L, Barrett T, Yuan J, Hatzidimitriou G, McCann UD, Becker KG, Donovan DM, Ricaurte GA.

J Neurosci. 2002 Jan 1;22(1):274-83.

47.

Assessing long-term effects of MDMA (Ecstasy).

Ricaurte GA, McCann UD.

Lancet. 2001 Dec 1;358(9296):1831-2. No abstract available.

PMID:
11741618
48.

"Ecstasy" and serotonin neurotoxicity: new findings raise more questions.

McCann UD, Ricaurte GA, Molliver ME.

Arch Gen Psychiatry. 2001 Oct;58(10):907-8. No abstract available.

PMID:
11576027
49.

A murine dopamine neuron-specific cDNA library and microarray: increased COX1 expression during methamphetamine neurotoxicity.

Barrett T, Xie T, Piao Y, Dillon-Carter O, Kargul GJ, Lim MK, Chrest FJ, Wersto R, Rowley DL, Juhaszova M, Zhou L, Vawter MP, Becker KG, Cheadle C, Wood WH 3rd, McCann UD, Freed WJ, Ko MS, Ricaurte GA, Donovan DM.

Neurobiol Dis. 2001 Oct;8(5):822-33.

PMID:
11592851

Supplemental Content

Loading ...
Support Center